دورية أكاديمية

Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations.

التفاصيل البيبلوغرافية
العنوان: Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations.
المؤلفون: Chung C; Department of Pharmacy, Houston Methodist West Hospital, Houston, TX, USA., Yeung VTY; State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR., Wong KCW; State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR.
المصدر: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2023 Sep; Vol. 29 (6), pp. 1343-1360. Date of Electronic Publication: 2022 Aug 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-092X (Electronic) Linking ISSN: 10781552 NLM ISO Abbreviation: J Oncol Pharm Pract Subsets: MEDLINE
أسماء مطبوعة: Publication: London : SAGE Publications
Original Publication: Norwalk, CT : Appleton & Lange, c1995-
مواضيع طبية MeSH: Breast Neoplasms*/genetics, Humans ; Female ; Prognosis ; BRCA1 Protein/genetics ; Microsatellite Instability ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; BRCA2 Protein/genetics
مستخلص: Objective: To evaluate and validate the recent and emerging data for prognostic and predictive biomarkers with therapeutic targets in breast cancer.
Data Sources: A literature search from January 2015 to March 2022 was performed using the key terms breast cancer , clinical practice guidelines , gene mutations , genomic assay , immune cancer therapy , predictive and/or prognostic biomarkers , and targeted therapies .
Study Selection and Data Extraction: Relevant clinical trials, meta-analyses, seminal articles, and published evidence- and consensus-based clinical practice guidelines in the English language were identified, reviewed and evaluated.
Data Synthesis: Breast cancer is a biologically heterogeneous disease, leading to wide variability in treatment responses and survival outcomes. Biomarkers for breast cancer are evolving from traditional biomarkers in immunohistochemistry (IHC) such as estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor type 2 (HER2) to genetic biomarkers with therapeutic implications (e.g. breast cancer susceptibility gene 1/2 [ BRCA1/2 ], estrogen receptor α [ ESR1] gene mutation, HER2 gene mutation, microsatellite instability [MSI], phosphatidylinositol 3-kinase catalytic subunit 3Cα [ PIK3CA ] gene mutation, neurotrophic tyrosine receptor kinase [ NTRK ] gene mutation). In addition, current data are most robust for biomarkers in immunotherapy (e.g. programmed cell death receptor ligand-1 [PD-L1], microsatellite instability-high [MSI-H] or deficient mismatch repair [dMMR]). Oncotype DX assay remains the best validated gene expression assay that is both predictive and prognostic whereas MammaPrint is prognostic for genomic risk.
Conclusions: Biomarker-driven therapies have the potential to confer greater therapeutic advantages than standard-of-care therapies. The purported survival benefits associated with biomarker-driven therapies should be weighed against their potential harms.
فهرسة مساهمة: Keywords: biomarkers; breast cancer; immune cancer therapy; predictive or prognostic; targeted therapy
المشرفين على المادة: 0 (BRCA1 protein, human)
0 (BRCA1 Protein)
0 (Biomarkers, Tumor)
0 (BRCA2 protein, human)
0 (BRCA2 Protein)
تواريخ الأحداث: Date Created: 20220816 Date Completed: 20231023 Latest Revision: 20231023
رمز التحديث: 20231023
DOI: 10.1177/10781552221119797
PMID: 35971313
قاعدة البيانات: MEDLINE